This experiment first established a model of spleen deficiency type ulcerative colitis (UC),and then used high-throughput liquid chip technology to detect inflammatory cytokines in rat serum.HE staining was used to grade inflammation in colon tissue.All of the above are used to verify the pharmacological effect of Banxia Xiexin Tang(BXT) on spleen deficiency type colitis.Secondly,UPLC-Q-Orbitrap HRMS was used to analyze the components of BXT in rat blood,combined with network pharmacology,to explore the mechanism of action of BXT in treating UC of spleen deficiency type.The results showed that UC could increase the level of inflammatory factors interleukin-1α(IL-1α),interleukin-10(IL-10),interleukin-18(IL-18),interferon-γ(IFN-γ) and tumor necrosis factor-α(TNF-α) in rat serum;BXT can decrease the content of serum inflammatory factor,and the effect of BXT high dose group (20 g/kg) was the most obvious,with no obvious infiltration of inflammatory cells.it is suggested that BXT has a certain therapeutic effect on UC with spleen deficiency.A total of 20 components were found in rat serum. On this basis,network pharmacological research has screened 87 targets targets related to BXT in the treatment of UC,involving inflammatory response,inflammatory response regulation,microbial response and other biological processes,participating in the IL-17 signaling pathway,Lipid and atherosclerosis,AGE-RAGE signaling pathway in diabetic complications and TNF signaling pathway.The results suggest that the treatment of spleen deficiency type UC with BXT may be related to the inhibition of intestinal inflammation,the regulation of intestinal microbes and the protection of intestinal barrier,so as to achieve the therapeytic effect of UC.